76 related articles for article (PubMed ID: 24574270)
1. Novel vaccine delivery system induces robust humoral and cellular immune responses based on multiple mechanisms.
Wang YQ; Wu J; Fan QZ; Zhou M; Yue ZG; Ma GH; Su ZG
Adv Healthc Mater; 2014 May; 3(5):670-81. PubMed ID: 24574270
[TBL] [Abstract][Full Text] [Related]
2. Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization.
Wu Y; Wei W; Zhou M; Wang Y; Wu J; Ma G; Su Z
Biomaterials; 2012 Mar; 33(7):2351-60. PubMed ID: 22192540
[TBL] [Abstract][Full Text] [Related]
3. Improving adjuvanticity of quaternized chitosan-based microgels for H5N1 split vaccine by tailoring the particle properties to achieve antigen dose sparing effect.
Wang YQ; Fan QZ; Liu Y; Yue H; Ma XW; Wu J; Ma GH; Su ZG
Int J Pharm; 2016 Dec; 515(1-2):84-93. PubMed ID: 27697632
[TBL] [Abstract][Full Text] [Related]
4. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
Ninomiya A; Imai M; Tashiro M; Odagiri T
Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
[TBL] [Abstract][Full Text] [Related]
5. Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge.
Prabakaran M; Kolpe AB; He F; Kwang J
Vaccine; 2013 Feb; 31(10):1385-92. PubMed ID: 23328313
[TBL] [Abstract][Full Text] [Related]
6. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
7. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z
Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049
[TBL] [Abstract][Full Text] [Related]
8. Cross-protection against influenza virus infection by intranasal administration of M1-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Fang F; Zheng M; Chen Z
Vaccine; 2010 Nov; 28(48):7690-8. PubMed ID: 20870054
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity, protective efficacy and mechanism of novel CCS adjuvanted influenza vaccine.
Even-Or O; Samira S; Rochlin E; Balasingam S; Mann AJ; Lambkin-Williams R; Spira J; Goldwaser I; Ellis R; Barenholz Y
Vaccine; 2010 Sep; 28(39):6527-41. PubMed ID: 20412874
[TBL] [Abstract][Full Text] [Related]
10. Protective immunity elicited by a pseudotyped baculovirus-mediated bivalent H5N1 influenza vaccine.
Wu Q; Xiao S; Fan H; Li Y; Xu J; Li Z; Lu W; Su X; Zou W; Jin M; Chen H; Fang L
Antiviral Res; 2011 Dec; 92(3):493-6. PubMed ID: 22020305
[TBL] [Abstract][Full Text] [Related]
11. Cross-protection against influenza virus infection by intranasal administration of M2-based vaccine with chitosan as an adjuvant.
Sui Z; Chen Q; Wu R; Zhang H; Zheng M; Wang H; Chen Z
Arch Virol; 2010 Apr; 155(4):535-44. PubMed ID: 20195654
[TBL] [Abstract][Full Text] [Related]
12. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant.
Zhao G; Du L; Xiao W; Sun S; Lin Y; Chen M; Kou Z; He Y; Lustigman S; Jiang S; Zheng BJ; Zhou Y
Vaccine; 2010 Oct; 28(44):7233-40. PubMed ID: 20732469
[TBL] [Abstract][Full Text] [Related]
13. Needle-free skin patch delivery of a vaccine for a potentially pandemic influenza virus provides protection against lethal challenge in mice.
Garg S; Hoelscher M; Belser JA; Wang C; Jayashankar L; Guo Z; Durland RH; Katz JM; Sambhara S
Clin Vaccine Immunol; 2007 Jul; 14(7):926-8. PubMed ID: 17494637
[TBL] [Abstract][Full Text] [Related]
14. Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.
Patel A; Gray M; Li Y; Kobasa D; Yao X; Kobinger GP
Vaccine; 2012 Jan; 30(3):626-36. PubMed ID: 22119588
[TBL] [Abstract][Full Text] [Related]
15. Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination.
van Maurik A; Sabarth N; Dacho HS; Brühl P; Schwendinger M; Crowe BA; Noel Barrett P; Kistner O; Keith Howard M
Vaccine; 2010 Feb; 28(7):1778-85. PubMed ID: 20018265
[TBL] [Abstract][Full Text] [Related]
16. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
[TBL] [Abstract][Full Text] [Related]
17. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
[TBL] [Abstract][Full Text] [Related]
18. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
[TBL] [Abstract][Full Text] [Related]
19. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
[TBL] [Abstract][Full Text] [Related]
20. Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice.
Madhun AS; Haaheim LR; Nilsen MV; Cox RJ
Vaccine; 2009 Dec; 27(52):7367-76. PubMed ID: 19781678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]